Clinical trials: Streptococcus Pneumonia
Severe Community-acquired Pneumonia
Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management
Severe community-acquired pneumonia (CAP) and community-acquired aspiration pneumonia (CAAP) are common reasons for adult emergency department visits and subsequent admission to the intensive care unit (ICU).
- Trial name
- CAP-ICU (NCT07322549)
- Testing
- Susceptibility to AMC, Susceptibilty to 3GC
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Pneumonia, Pneumococcal, Vaccine
Pneumonia Vaccine Education Intervention Study
The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine.
- Trial name
- PVI (NCT06136832)
- Testing
- Pneumococcal Vaccine Education
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Geisinger Clinic
Streptococcus Pneumoniae Pneumonia
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
In the treatment of pneumococcal diseases, the common use of penicillin-based antimicrobial agents has led to drug resistance, which has become a global challenge. Therefore, disease prevention through vaccination is essential.
- Trial name
- NCT07035054
- Testing
- low dose-1, low dose-2, high dose
- Where
- China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumococcal Pneumonia, Influenza
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza…
- Trial name
- NCT02592486
- Testing
- Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®, Sequential administration of Pneumovax NP® and Fluvic HA syringe®
- Where
- Japan
- Volunteers
- 162 people
- Sponsor
- Kameda Medical Center
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
The long-term goals of this study are (a) to understand the biological underpinnings for the increased incidence of community-acquired pneumonia in patients with chronic obstructive pulmonary disease (COPD) who are treated with…
- Trial name
- NCT03034642
- Testing
- Bronchoscopy with bilateral bronchoalveolar lavages
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Ann Arbor Healthcare System
Streptococcal Pneumonia, HIV/AIDS
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults
HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. Pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is…
- Trial name
- NCT03838497
- Testing
- Prevenar13
- Volunteers
- 70 people
- Sponsor
- Korea University Guro Hospital
Pneumonia, Streptococcus Pneumoniae
Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status
Community acquired pneumonia (CAP) is an important health problem with significant morbidity, mortality and cost. The most identified pathogen in CAP is Streptococcus pneumoniae.
- Conditions
- Pneumonia, Streptococcus Pneumoniae, Immune Response
- Trial name
- CAPolista (NCT02141009)
- Testing
- Prevnar 13
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- St. Antonius Hospital
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (384 subjects): 1st dose : combined vaccination of COVAX+IIV4, 2nd dose: combined vaccination of COVAX+PPV23; Control Group A (384 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, Covid19
- Trial name
- NCT04790851
- Testing
- COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Invasive Group A Beta-Haemolytic Streptococcal Disease
Severe Group A Streptococcus Infections in Paris, France, 2018-2023
Streptococcus pyogenes, commonly referred to as Group A Streptococcus (GAS), has the ability to induce a diverse range of illnesses.
- Trial name
- IGASI (NCT06297122)
- Testing
- Collection of data from the patient's medical file
- Where
- France
- Volunteers
- 269 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sepsis, Severe Community-acquired Pneumonia (sCAP)
Molecular Biomarkers for Sepsis
This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and…
- Conditions
- Sepsis, Severe Community-acquired Pneumonia (sCAP), Infection, Bacterial
- Trial name
- NCT04280354
- Testing
- compare data patterns by data-driven algorithms to determine sepsis, compare data patterns by data-driven algorithms to predict sepsis-related mortality
- Where
- 15 sites in Switzerland
- Volunteers
- 3 people
- Sponsor
- University Hospital, Basel, Switzerland
Pneumococcal Pneumonia, Pneumonia, Bacterial
Phase I to Test a New Pneumococcal Vaccine
To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.
- Trial name
- NCT03303976
- Testing
- Bioconjugate pneumococcal vaccine, Multivalent plain polysaccharide vaccine
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Pneumonia, Pneumococcal
Evaluation of PCV Schedules in a Naive Population in Vietnam
The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci.
- Trial name
- NCT02961231
- Testing
- PCV 2p+1, PCV 3p+0, PCV 1p+1
- Where
- Vietnam
- Volunteers
- 18,652 people, healthy volunteers welcome
- Sponsor
- Nagasaki University
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria…
- Trial name
- NCT01086397
- Testing
- Urine sample collection
- Where
- 14 sites in United States
- Volunteers
- 782 people
- Sponsor
- Pfizer
Pneumococcal Infections
Phase I Clinical Trial of a Candidate PCV13 in Healthy People
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.
- Trial name
- NCT05602480
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of the pneumococcal conjugate vaccine, co-admin with a 1st dose or a 2nd dose of MMRV vaccine at 12-14 or respectively 14-16 months of age…
- Trial name
- NCT00370227
- Testing
- 10 valent pneumococcal conjugate (vaccine)
- Where
- 8 sites in Finland
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal Infections
Humoral Determinants of Immunity to Pneumococcal Infection
The purpose of this study is to determine whether there are differences in the level of antibody to capsular polysaccharides of S.
- Conditions
- Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
- Trial name
- NCT00304382
- Testing
- Prevnar, Pneumovax
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- VA Office of Research and Development
Infection, Lung Parenchyma
Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact.
- Trial name
- PPAC (NCT05661513)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Pneumonia, Pneumococcal
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered…
- Trial name
- NCT05526716
- Testing
- V116, QIV
- Where
- 56 sites in United States
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Streptococcal Pneumonia, Nasopharyngeal Diseases
PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae
A parallel-group, randomized, open-label study will be performed in subjects receiving PCV7 and subjects receiving controlled vaccine Hib vaccine, to claim the efficacy of PCV7 in the prevention of NP carriage of vaccine-serotype…
- Conditions
- Streptococcal Pneumonia, Nasopharyngeal Diseases, Vaccination Adverse Event
- Trial name
- NCT02133469
- Testing
- PCV7 (Pneumococcal 7-Valent Conjugate Vaccine), Hib Vaccine
- Where
- 9 sites in China
- Volunteers
- 3,281 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Pneumonia, Pneumococcal
Immunogenicity and Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in 2-month-old and 3-month-old Healthy Volunteers
The purpose of this study is to evaluate Immunogenicity and safety of 15-Valent Pneumococcal Conjugate Vaccine in healthy volunteers aged 2 and 3 months.
- Trial name
- NCT04357522
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine, 13-Valent Pneumococcal Conjugate Vaccine
- Where
- 3 sites in China
- Volunteers
- 1,950 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd